3-(3-METHYL-2-THIOXO-2,3-DIHYDRO-BENZOIMIDAZOL-1-YL)-PROPIONIC ACID
- $378 - $874
- Product name: 3-(3-METHYL-2-THIOXO-2,3-DIHYDRO-BENZOIMIDAZOL-1-YL)-PROPIONIC ACID
- CAS: 247128-23-0
- MF: C11H12N2O2S
- MW: 236.29
- EINECS:
- MDL Number:MFCD00725603
- Synonyms:1-(2-CARBOXYETHYL)-3-METHYLBENZIMIDAZOLE-2(1H)-THIONE;3-(3-METHYL-2-THIOXO-2,3-DIHYDRO-BENZOIMIDAZOL-1-YL)-PROPIONIC ACID;1H-Benzimidazole-1-propanoic acid, 2,3-dihydro-3-methyl-2-thioxo-
3 prices
Selected condition:
Brand
- American Custom Chemicals Corporation
- Crysdot
- Matrix Scientific
Package
- 500MG
- 1g
- 5g
- ManufacturerAmerican Custom Chemicals Corporation
- Product numberCHM0084990
- Product description3-(3-METHYL-2-THIOXO-2,3-DIHYDRO-BENZOIMIDAZOL-1-YL)-PROPIONIC ACID 95.00%
- Packaging500MG
- Price$768.08
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11159423
- Product description3-(3-Methyl-2-thioxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)propanoicacid 97%
- Packaging5g
- Price$874
- Updated2021-12-16
- Buy
- ManufacturerMatrix Scientific
- Product number009918
- Product description3-(3-Methyl-2-thioxo-2,3-dihydro-benzoimidazol-1-yl)-propionic acid
- Packaging1g
- Price$378
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
American Custom Chemicals Corporation | CHM0084990 | 3-(3-METHYL-2-THIOXO-2,3-DIHYDRO-BENZOIMIDAZOL-1-YL)-PROPIONIC ACID 95.00% | 500MG | $768.08 | 2021-12-16 | Buy |
Crysdot | CD11159423 | 3-(3-Methyl-2-thioxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)propanoicacid 97% | 5g | $874 | 2021-12-16 | Buy |
Matrix Scientific | 009918 | 3-(3-Methyl-2-thioxo-2,3-dihydro-benzoimidazol-1-yl)-propionic acid | 1g | $378 | 2021-12-16 | Buy |
Properties
Boiling point :417.6±47.0 °C(Predicted)
Density :1.42±0.1 g/cm3(Predicted)
pka :4.20±0.10(Predicted)
Density :1.42±0.1 g/cm3(Predicted)
pka :4.20±0.10(Predicted)
Safety Information
Symbol(GHS): | ||||||||
---|---|---|---|---|---|---|---|---|
Signal word: | ||||||||
Hazard statements: |
|
|||||||
Precautionary statements: |
|